OSE Immunotherapeutics ^Competitor

OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes, France, founded in 2016. The company specializes in immuno-oncology and immuno-inflammation therapies, focusing on first-in-class immunotherapies that modulate the immune system to target cancer and chronic inflammatory diseases.

OSE operates with proprietary drug discovery platforms and a robust clinical pipeline developed through collaborations with academic institutions and industry partners, including AbbVie and Boehringer Ingelheim. Their research and development efforts emphasize T-cell activation, immune checkpoint regulation, and myeloid cell-mediated inflammation control. Key products in their pipeline include Tedopi®, a neoepitope-based cancer vaccine in Phase 3 trials, and OSE-279, an anti-PD-1 monoclonal antibody for solid tumors and lymphomas. The company is committed to addressing unmet medical needs in oncology and inflammation through innovative therapies.